[1] Vojdeman FJ, Herman SE, Kirkby N, et al.Soluble CD52 is an indicator of disease activity in chronic lymphocytic leukemia[J]. Leukemia & Lymphoma, 2017:1. [2] Osterborg A, Dyer MJ, Bunjes D, et al.Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia[J]. Journal of Clinical Oncology, 1997, 15(4):1567-1574. [3] Von KS, Pryce G, Giovannoni G, et al.Depletion of CD52 positive cells inhibits the development of CNS autoimmune disease, but deletes an immune-tolerance promoting CD8 T cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis[J]. Immunology, 2017, 150(4):444-455. [4] Pant AB, Yan W, Mielcarz DW, et al.Alteration of CD39 + Foxp3 + CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment[J]. Journal of Neuroimmunology, 2017, 303:22-30. [5] Clark SL, Tse JY, Fisher DC, et al.Histopathologic spectrum of hypersensitivity reactions associated with anti-CD52 therapy(alem-tuzumab)[J]. Journal of Cutaneous Pathology, 2016, 43(11):989-993. [6] Berger T, Elovaara I, Fredrikson S, et al.Alemtuzumab use in clinical practice:Recommendations from european multiple sclerosis experts[J]. Cns Drugs, 2016, 31(1):1-18. [7] Mcewan L, Caon C, Chieffe C, et al.Best practices in alemtuzumab administration:practical recommendations for infusion in patients with multiple sclerosis[J]. Journal of Infusion Nursing the Official Publication of the Infusion Nurses Society, 2016, 39(2):93. [8] 中国药典2015 年版. 四部[S]. 2015:250, 374. ChP 2015. Vol Ⅳ[S]. 2015:250, 374 [9] Bongers J, Cummings JJ, Ebert MB, et al.Validation of a peptide mapping method for a therapeutic monoclonal antibody:what could we possibly learn about a method we have run 100 times?[J]. Journal of Pharmaceutical & Biomedical Analysis, 2000, 21(6):1099. [10] Chirino AJ, Miresluis A.Characterizing biological products and assessing comparability following manufacturing changes[J]. Nature Biotechnology, 2004, 22(11):1383-91. [11] Zhang J, Qin T, Xu L, et al.Development and validation of a peptide mapping method for the characterization of adalimumab with QDa Detector[J]. Chromatographia, 2016, 79(7-8):395-403. [12] Cunagin W, Musselman J, Taylor R, et al.Florida’s return on investment from pavement research and development[J]. Transportation Research Record Journal of the Transportation Research Board, 2014, 2455(-1):10-18. [13] Herron H, Roy S, Bohn B, et al.Addressing climate change within disaster risk management:A practical guide for IDB project preparation[R]. Inter-American Development Bank, 2015. |